Abstracts Archive - Page 2177 of 2607 - ACR Meeting Abstracts

Abstract Number: 840 • 2014 ACR/ARHP Annual Meeting
Vascular Calcifications on Hand and Wrist Radiographs Are Associated with Cardiovascular Risk Factors, Antigen-Specific Anti-Citrullinated Protein Antibodies, and Mortality in Rheumatoid Arthritis
E. Blair Solow¹, Fang Yu², Geoffrey M. Thiele³, Jeremy Sokolove^4,5, William H. Robinson^6,7, Zachary M. Pruhs³, Kaleb Michaud^8,9, Alan R. Erickson⁹, Harlan Sayles⁹, Gail S. Kerr¹⁰, Angelo L. Gaffo¹¹, Liron Caplan¹², Lisa A. Davis¹³, Grant W. Cannon¹⁴, Andreas M. Reimold¹⁵, Joshua Baker¹⁶, Pascale Schwab^17,18, Daniel Anderson⁹ and Ted R. Mikuls⁹, ¹Internal Medicine, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁵Stanford University School of Medicine, Stanford, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸National Data Bank for Rheumatic Diseases, Wichita, KS, ⁹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁰Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ¹¹Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, ¹²Div of Rheumatology, Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ¹³Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ¹⁴Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ¹⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁶Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁷Department of Internal Medicine, Division of Rheumatology, Portland VA Medical Center, Portland, OR, ¹⁸Internal Medicine, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased mortality due to cardiovascular disease (CVD). Select antigen-specific anti-citrullinated protein antibodies (ACPA) are associated with atherosclerotic…
Abstract Number: 859 • 2014 ACR/ARHP Annual Meeting
TGF-β3-Producing CD4⁺CD25^–LAG3⁺ Regulatory T Cells Control B Cell Responses
Tomohisa Okamura¹, Kaoru Morita¹, Mariko Inoue¹, Toshihiko Komai¹, Yukiko Iwasaki¹, Shuji Sumitomo¹, Shinichiro Nakachi¹, Hirofumi Shoda², Keishi Fujio² and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and associated with a wide range of clinical manifestations. Recent case-control association…
Abstract Number: 858 • 2014 ACR/ARHP Annual Meeting
ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets
Li Chun Wang¹, Stuart Perper¹, Annette Schwartz², Christian Goess³, Liz O'connor⁴, Dawna Hartman², Candace Graff², Andrew Souers⁵, Joel Leverson⁵, Steven Elmore⁵ and Lisa Olson², ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, North Chicago, IL
Background/Purpose Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. Navitoclax, a selective inhibitor of both BCL-2 and BCL-X(L) demonstrated…
Abstract Number: 856 • 2014 ACR/ARHP Annual Meeting
A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus
Silvio M. Vieira¹, Andrew Yu¹, Michael Hiltesperger¹, Odelya E. Pagovich¹, Eleni Tiniakou¹, William Ruff², John Sterpka¹ and Martin Kriegel^2,3, ¹Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, New Haven, CT, ³Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The etiology of lupus-associated antiphospholipid syndrome (APS) is unknown but microbial triggers have been implicated in transient antiphospholipid antibody production in both mice and…
Abstract Number: 854 • 2014 ACR/ARHP Annual Meeting
Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial
Chi Chiu Mok¹, Angela Li², Kar Li Chan¹ and Ling Yin Ho¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Radiology, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To compare the efficacy of golimumab(GLM) and pamidronate(PAM) in the treatment of SpA.Methods Inclusion criteria: (1) patients ≥18 years of age; (2) fulfills the…
Abstract Number: 855 • 2014 ACR/ARHP Annual Meeting
Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Etanercept
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Previous studies evaluating predictors of major clinical response in patients with non-radiographic axial SpA (nr-axSpA) receiving treatment with anti-TNF agents have been limited by…
Abstract Number: 853 • 2014 ACR/ARHP Annual Meeting
Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis – a Study from the ARTIS and Danbio Registers
Johan Askling¹, Lene Dreyer², Merete Lund Hetland³, Lennart Jacobsson⁴, Lars-Erik Kristensen⁵, Bente Glintborg⁶, . ARTIS and DANBIO study groups⁷ and Karin Hellgren⁸, ¹Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²Gentofte University Hospital, Hellreup, Denmark, ³Glostrup University Hospital, Glostrup, Denmark, ⁴Sahlgrenska Academy, Gothenburg, Sweden, ⁵Lund University, Lund, Sweden, ⁶Gentofte University Hospital, Gentofte, Denmark, ⁷Karolinska Institutet, stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden
Background/Purpose Most studies of the safety profile of TNF inhibitors (TNFi) - in particular in relation to cancer risks - have been performed in patients…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…
Abstract Number: 857 • 2014 ACR/ARHP Annual Meeting
Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors
Chaim O. Jacob, Ning Yu and William Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: BAFF, a potent B cell survival factor, is an established therapeutic target in SLE, with the anti-BAFF antibody, belimumab, being FDA-approved for the treatment…
Abstract Number: 831 • 2014 ACR/ARHP Annual Meeting
Bisphosphonates and Risk of Acute Pseudogout: A Case-Control Study in the Clinical Practice Research Datalink (CPRD)
Edward Roddy, Sara Muller, Zoe Paskins, Samantha Hider, Milisa Blagojevic-Bucknall and Christian Mallen, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom
Background/Purpose: Acute pseudogout is the most dramatic clinical manifestation of calcium pyrophosphate crystal deposition (CPPD). CPPD is most commonly sporadic and age-related but can rarely…
Abstract Number: 830 • 2014 ACR/ARHP Annual Meeting
Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1
Raymond P. Warrell Jr.¹, Anna Klukovits², Keith Barnes³, Chitkala Satyanarayana⁴, Chris Cheeseman⁵ and John Piwinski¹, ¹Relburn-Metabolomics, Inc., Westfield, NJ, ²SOLVO Biotechnology, Budapest, Hungary, ³AMRI, Albany, NY, ⁴AMRI, Singapore, Singapore, ⁵University of Alberta, Alberta, AB, Canada
Background/Purpose: A prototype anticancer drug (RLBN1001) induced marked hypouricemia in studies of > 350 human subjects. Preliminary exploration suggested dual effects on uric acid (UA)…
Abstract Number: 829 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Deposit of Monosodium Urate Crystals Associates to a More Severe Coronary Calcification in Hyperuricemic Patients with Acute Coronary Syndrome
Mariano Andrés¹, María Amparo Quintanilla², Francisca Sivera¹, Paloma Vela^3,4 and Juan Miguel Ruiz-Nodar⁵, ¹Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ²Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, ³Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ⁴Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. Monosodium urate (MSU) crystals are found in ~25% of patients with asymptomatic hyperuricemia (AH)…
Abstract Number: 828 • 2014 ACR/ARHP Annual Meeting
Extent of Urate Deposition in Asymptomatic Hyperuricemia and Symptomatic Gout: A Dual Energy Computed Tomography Study
Nicola Dalbeth¹, Meaghan House¹, Opetaia Aati¹, Paul Tan², Christopher Franklin², Anne Horne¹, Gregory Gamble¹, Lisa K. Stamp³, Anthony Doyle² and Fiona M. McQueen⁴, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Background/Purpose: Recent studies have reported that ultrasound features of urate crystal deposition are present in some asymptomatic individuals with hyperuricemia, suggesting that subclinical urate deposition…
Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Na Lu¹, Yuqing Zhang¹, Alberto Ascherio², Miguel Hernan², Tuhina Neogi¹, Maureen Dubreuil^3,4 and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…
Abstract Number: 826 • 2014 ACR/ARHP Annual Meeting
Comparison of Classification Criteria for Gout Using Monosodium Urate Crystal Identification By a Certified Examiner As the Gold-Standard in a Large Multi-National Study
William Taylor¹, Nicola Dalbeth², Jaap Fransen³, Tuhina Neogi⁴, H. Ralph Schumacher Jr.⁵ and Tim Jansen⁶, ¹Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Radboud University, Nijmegen, Netherlands, ⁴Boston University School of Medicine, Boston, MA, ⁵University of Pennsylvania VA Medical Center, Philadelphia, PA, ⁶Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Most gout is managed in primary care where the diagnosis seldom relies upon identification of MSU crystals. Several classification criteria for gout have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].